Dendritic cell-based immunotherapy of malignant gliomas
Related Experiment Video
Updated: Aug 21, 2026
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
Prahlad Parajuli1, Andrew E Sloan
1Department of Neurosurgery, Wayne State University and Karmanos Cancer Institute, Detroit, Michigan 48201, USA. pparajuli@neurosurgery.wayne.edu
Abstract:
The failure of conventional treatment modalities for gliomas, in spite of tremendous progress in research in the past two decades, has led to increasing interest in alternative treatment strategies, including immunotherapy. It has become evident that vaccination with dendritic cells (DC), designed to express tumor antigens, is a potent strategy to elicit anti-tumor immune response in both pre-clinical and clinical settings. Various methods have been applied in order to induce DC to express tumor antigens including: pulsing with isolated tumor peptides or whole tumor lysate; fusion with tumor cells; and pulsing with apoptotic tumor cells. Herein, we review the recent progress in DC biology with regard to tumor immunity and discuss current DC-based strategies and future prospects in immunotherapy for malignant gliomas.
Insights
Conventional glioma treatments are failing, prompting interest in immunotherapy. Dendritic cell (DC) vaccines expressing tumor antigens show promise for eliciting anti-tumor immune responses, offering new hope for malignant gliomas.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Conventional treatments for malignant gliomas have limited efficacy.
- Immunotherapy, particularly using dendritic cells (DCs), is emerging as a promising alternative.
Purpose of the Study:
- To review recent advancements in dendritic cell (DC) biology related to tumor immunity.
- To discuss current DC-based immunotherapy strategies for malignant gliomas.
- To explore future prospects for DC-based cancer vaccines.
Main Methods:
- Review of preclinical and clinical studies on dendritic cell (DC) vaccination.
- Analysis of methods for inducing tumor antigen expression in DCs (peptide pulsing, tumor lysate, cell fusion, apoptotic cell pulsing).
Main Results:
- Dendritic cell (DC) vaccination is a potent strategy to induce anti-tumor immune responses.
- Various methods exist to load DCs with tumor antigens for enhanced immunogenicity.
Conclusions:
- Dendritic cell (DC)-based immunotherapy represents a significant area of research for treating malignant gliomas.
- Further research into DC biology and vaccination strategies is crucial for advancing glioma treatment.
